Dr. Peter Kolchinsky is an Independent Director at Icosavax, Inc., at Wave Life Sciences Ltd., a Chairman & Chief Executive Officer at Research Alliance Corp. II, an Independent Non-Executive Director at Forma Therapeutics Holdings, Inc., and a Managing Partner at RA Capital Management LP.
He is on the Board of Directors at Icosavax, Inc., Forma Therapeutics Holdings, Inc., Sojournix, Inc., Wave Life Sciences Ltd., Adeo Health Science, Inc., Cellscape Corp., Enlight Biosciences LLC, Freenome Holdings, Inc., Ivantis, Inc., Lantos Technologies, Inc., Periphagen Holdings, Inc., PiloFocus, Inc. and The American Fertility Association. At RA Capital, Dr. Kolchinsky is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools and serves on the boards of publicly- and privately-held life science companies.
He also leads the firmís engagement and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policymakers, and industry.
Dr. Kolchinsky was previously employed as a Chairman & Chief Executive Officer by Therapeutics Acquisition Corp., an Independent Director by Synthorx, Inc., by G1 Therapeutics, Inc., by Dicerna Pharmaceuticals, Inc., a Director-Science & Technology by National Academies of Sciences, and a Member-National Academies Board by Global Science & Technology, Inc.
He also served on the board at Calimmune, Inc., Medeor Therapeutics, Inc. and ZipLine Medical, Inc.
He holds a BA from Cornell University and a PhD in Virology from Harvard University.